REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) — Gynesonics® Inc., a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, is pleased to announce that it has secured an incremental $42.5 million in financing (total of $67.2M inclusive of initial April 2023 financing). The round was led by existing Gynesonics investors Amzak Healthcare, Endeavour Vision, Kaiser Permanente Ventures, Runway Growth Capital, and Bain Capital; with new investments coming from MVM Partners as well as several other healthcare investors excited about Gynesonics’ commercial advances.

“Gynesonics continues to lay a strong foundation for success, having achieved a number of important commercial milestones in the most recent quarters,” said Joyce Erony, General Partner, Amzak Ventures. “The Company is very well positioned to continue the acceleration of its growth going forward. Amzak and our fellow Gynesonics investors are very excited about the company’s prospects to become the leading long-term solution in the treatment of symptomatic fibroids.”

Hugo Harrod of MVM Partners, the newest venture capital fund investing in Gynesonics commented, “Uterine fibroids cause suffering to millions of women. MVM is glad to support Gynesonics in offering a uterus-preserving, incisionless alternative to hysterectomy and myomectomy.”

“This funding will enable Gynesonics to continue to expand commercial operations and provide millions of patients suffering from symptomatic fibroids a safe and efficacious minimally invasive treatment,” said Skip Baldino, President and CEO of Gynesonics. “With 275M+ U.S. covered lives (including 19 of the top 20 commercial payers) covering Sonata® and our new Category 1 code going live in January, we are excited to accelerate our commercial efforts in the U.S. as well as Europe.”

About Gynesonics
As pioneers in women’s health, Gynesonics is committed to developing and delivering minimally invasive, incision-free, uterus-preserving, transcervical technologies for diagnostic and therapeutic applications. Gynesonics’ flagship product, the Sonata System®, is the first FDA-cleared medical device for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids, a medical condition affecting roughly 80% of adult women. Prior to the Sonata System, fibroid removal was limited to invasive medical procedures, like a hysterectomy, which carries greater risk and significantly more recovery time.

Sonata’s innovative technology removes fibroids in a roughly 45-minute outpatient procedure with most patients resuming regular activity the next day, representing a significant medical advancement that makes treatment of the condition more accessible. 

The Sonata System is CE-marked and is approved for sale in the European Union, the United Kingdom, Switzerland, and the United States. For more information on Sonata, visit Gynesonics headquarters is in Redwood City, CA. For more information, visit

Company Contact:
Tara Murphy, Senior Director, Global Marketing & Advocacy, Gynesonics,, (215) 620-3004

Media Contact: 
David Gutierrez, Dresner Corporate Services,, (312) 780-7204

Latest news

Optinose’s XHANCE® Approved by FDA for Chronic Rhinosinusitis without Nasal Polyps
March 15, 2024

Full release here: Optinose’s XHANCE® Approved by FDA for Chronic Rhinosinusitis without Nasal Polyps

GT Medical Technologies Names Per Langoe As CEO
February 20, 2024

Full release here: GT Medical Technologies, Inc. Names Per Langoe As CEO

MVM invests in icotec
January 24, 2024

ALTSTAETTEN, Switzerland and EAST HARTFORD, Conn., Jan. 24, 2024 /PR Newswire/ — icotec ag, the leading company in the field of innovative spinal […]

SkyCell Featured in TechCrunch
October 31, 2023

Full release here: SkyCell raises $57M at a $600M valuation to build smart containers for pharmaceutical transport | TechCrunch

MVM invests in BioProtect
September 27, 2023

TZUR IGAL, Israel, Sept. 27, 2023 /PRNewswire/ — BioProtect Ltd, a private Med Tech company focused on providing innovative, biodegradable spacing solutions, announced today the […]

VitalConnect Secures over $30 Million in Oversubscribed Series F Financing
July 18, 2023

SAN JOSE, Calif.–(BUSINESS WIRE)–VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced closing on an oversubscribed […]

MVM invests in CurvaFix
July 14, 2023

BELLEVUE, Wash.–(BUSINESS WIRE)–CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, today announced the close of […]

Vertos Medical Secures $26 Million to Expand Commercialization Efforts and Develop Breakthrough Treatments for Chronic Low Back Pain
June 7, 2023

ALISO VIEJO, Calif., June 7, 2023 /PRNewswire/ — Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for […]

eXmoor pharma completes $35 million Series A to expand cell and gene therapy manufacturing capabilities
May 30, 2023

New GMP facility to complete eXmoor’s transition from consultancy to one-stop global cell and gene therapy partner Bristol, UK, May […]

GT Medical Technologies Raises $45 Million in Oversubscribed Series C Financing
March 23, 2023

TEMPE, Ariz., March 23, 2023 /PRNewswire/ — GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients […]